Dr. Hua Zhong and Dr. Baohui Han: Docetaxel Combined with Plinabulin in Second-Line Treatment for Mutation-Negative Advanced NSCLC Patients

Dr. Hua Zhong and Dr. Baohui Han: Docetaxel Combined with Plinabulin in Second-Line Treatment for Mutation-Negative Advanced NSCLC Patients

Modern advancements in oncology have introduced various breakthrough treatment options for lung cancer, which is now one of the most rapidly evolving solid tumors. To help clinicians stay updated on key advancements in this field, Oncology Frontier has partnered with Dr. Hua Zhong and Dr. Baohui Han of the Department of Respiratory and Critical Care Medicine at Shanghai Chest Hospital to launch the Zhōng & Huì Insights clinical progress series. Through in-depth analyses of high-quality clinical research in lung cancer, the series aims to elevate clinical practice standards. In this 24th installment, the professors discuss the results of the study titled "Efficacy and Safety of Docetaxel Combined with Plinabulin in Second-Line Treatment for Mutation-Negative Advanced NSCLC Patients," published in The Lancet Respiratory Medicine by Dr. Baohui Han as the first author.
Dr. Yige Bao: Perioperative Personalized Treatment of UTUC Based on ADC Drugs and the West China Experience

Dr. Yige Bao: Perioperative Personalized Treatment of UTUC Based on ADC Drugs and the West China Experience

Upper tract urothelial carcinoma (UTUC), encompassing renal pelvic and ureteral cancers, is relatively rare, with unique characteristics in the Chinese population, such as distinct disease features and molecular biology profiles. The 8th West China Uro-Oncology Tianfu Academic Conference, recently held in Chengdu, provided a platform to discuss how to better address the challenges in UTUC treatment and improve patient outcomes. In this event, Oncology Frontier interviewed Dr. Yige Bao from West China Hospital of Sichuan University, who shared insights into personalized perioperative treatment of UTUC with ADC drugs and the hospital's clinical experiences.
The 8th West China Uro-Oncology Tianfu Academic Conference丨Dr. Hongzhen Li: Advances in Radiotherapy for Urothelial Carcinoma

The 8th West China Uro-Oncology Tianfu Academic Conference丨Dr. Hongzhen Li: Advances in Radiotherapy for Urothelial Carcinoma

Urothelial carcinoma (UC) is one of the most common malignant tumors of the urinary system, encompassing bladder cancer, renal pelvic cancer, and ureteral cancer. Radiotherapy, as a critical treatment modality for tumors, has gained prominence in the comprehensive treatment of UC, offering hope for improved survival outcomes. During the 8th West China Urologic Oncology Academic Conference held in Chengdu, Oncology Frontier invited Dr. Hongzhen Li from Peking University First Hospital to share the latest advancements in radiotherapy for UC.
2024 WAAW丨Dr. Pengfei Shen: Why Urinary Tract Infections Trouble Women？

2024 WAAW丨Dr. Pengfei Shen: Why Urinary Tract Infections Trouble Women？

The third week of every November marks World Antimicrobial Awareness Week (WAAW). This year, WAAW adopts the theme: "Educate, Advocate, Act," aiming to raise public awareness about antimicrobial drugs, advocate for their appropriate use, and encourage action to combat antimicrobial resistance (AMR). In response to this call, Oncology Frontier invited Dr. Pengfei Shen from West China Hospital of Sichuan University to provide an informative overview of female urinary tract infections (UTIs), exploring why women are more prone to these infections, common symptoms, frequently used antibiotics, and the importance of responsible medication use to prevent antibiotic resistance.